| 摘要 |
The present invention relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is a mTOR inhibitor or a pharmaceutically acceptable salt thereof. |
